LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

LLY

992.23

+0.48%↑

JNJ

224.08

-0.79%↓

ABBV

205.44

-0.58%↓

UNH

367.84

+1.31%↑

AZN

185.21

+2.03%↑

Strona główna・Stock List・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Open

SectorHealthcare

473.69 1.06

Buy Sell

Overview

Share price change

24h

Current

Min

464.8

Max

476.94

Key metrics
By Trading Economics
Income	-314M 1.7B
Sales	-1.2B 11B
P/E Sector Avg	25.772 49.8
EPS	5.44
Dividend yield	0.38
Profit margin	15.048
Employees	125,000
EBITDA	-905M 2.3B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+34.17% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.38% 2.25%
Next Earnings	22 lip 2026
Next Dividend date	14 lip 2026
Next Ex Dividend date	12 cze 2026

Market Stats
By TradingEconomics
Market Cap	-24B 172B
Previous open	472.63
Previous close	473.69

News Sentiment

By Acuity

24%

76%

85 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

406.5 / 417.79 Support & Resistance

Thermo Fisher Scientific Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 kwi 2026, 13:56 UTC

Earnings

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 kwi 2026, 10:28 UTC

Earnings

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 sty 2026, 11:34 UTC

Earnings

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 paź 2025, 10:51 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 paź 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

22 paź 2025, 10:28 UTC

Earnings

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23 kwi 2026, 10:01 UTC

Earnings

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 kwi 2026, 10:01 UTC

Earnings

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 kwi 2026, 10:00 UTC

Earnings

Thermo Fisher 1Q Net $1.65B >TMO

23 kwi 2026, 10:00 UTC

Earnings

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 kwi 2026, 10:00 UTC

Earnings

Thermo Fisher 1Q EPS $4.43 >TMO

23 kwi 2026, 10:00 UTC

Earnings

Thermo Fisher 1Q Rev $11.01B >TMO

24 mar 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 sty 2026, 11:01 UTC

Earnings

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 sty 2026, 11:00 UTC

Earnings

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 sty 2026, 11:00 UTC

Earnings

Thermo Fisher 4Q Net $1.96B >TMO

29 sty 2026, 11:00 UTC

Earnings

Thermo Fisher 4Q Rev $12.22B >TMO

29 sty 2026, 11:00 UTC

Earnings

Thermo Fisher 4Q EPS $5.21 >TMO

29 sty 2026, 11:00 UTC

Earnings

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 paź 2025, 10:06 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 paź 2025, 10:05 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 paź 2025, 10:05 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 paź 2025, 10:04 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 paź 2025, 10:00 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 paź 2025, 10:01 UTC

Earnings

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 paź 2025, 10:00 UTC

Earnings

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 paź 2025, 10:00 UTC

Earnings

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 paź 2025, 10:00 UTC

Earnings

Thermo Fisher 3Q Rev $11.12B >TMO

22 paź 2025, 10:00 UTC

Earnings

Thermo Fisher 3Q Net $1.62B >TMO

Peer Comparison

Price change

Thermo Fisher Scientific Inc Forecast

Price Target

By TipRanks

34.17% upside

12 Months Forecast

Average 620.69 USD 34.17%

High 685 USD

Low 560 USD

Based on 15 Wall Street analysts offering 12 month price targets forThermo Fisher Scientific Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Thermo Fisher Scientific Inc - Dist in the past 3 months.

Technical Score

By Trading Central

406.5 / 417.79Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Sentiment

By Acuity

85 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar